Study of BND-22 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, dose escalation and expansion study designed to evaluate
the safety, tolerability, and preliminary anti-tumor activity of BND-22 administered alone
and in combination with pembrolizumab or with cetuximab. The study will enroll advanced
cancer patients with unresectable or metastatic disease who are refractory to or are not
candidates for standard approved therapy and will be comprised of two parts - an initial "3 +
3" dose escalation phase followed by a dose expansion phase.